November 19: The Week in Cancer News
HPV vaccine rates are higher when teens decide, colorectal cancer is on the rise in people under 50, and other cancer research news of the week from Cancer Today magazine.
Progress Against Cancer
HPV vaccine rates are higher when teens decide, colorectal cancer is on the rise in people under 50, and other cancer research news of the week from Cancer Today magazine.
Study: Short-term, severe calorie restriction can reduce sugar and other substances in blood that may feed cancer cells and boost the antitumor immune response. A diet involving short-term, severe calorie restriction was safe and...
The FDA has approved an immunotherapy known as immune checkpoint inhibition for the treatment of certain patients with kidney cancer. The U.S. Food and Drug Administration (FDA) has approved the immunotherapeutic pembrolizumab (Keytruda) for...
The U.S. Is behind in preventing cervical cancer through HPV vaccination, and more cancer news of the week from Cancer Today magazine.
Every cell in the human body contains about 300 million base pairs of double-stranded DNA that contribute to a range of processes throughout the cell, including gene expression, metabolic regulation, tissue identity, and protein...
“Patient-centered” study seeks to assess quality of time that patients live by measuring the “treatment-free survival” outcome. A treatment combining two immunotherapies gave patients with advanced kidney cancer a longer time without subsequent treatment...
U.S. map spotlights industrial hot spots for cancer-causing air pollution, and surgery delays after initial treatment impact survival for some patients with locally advanced rectal cancer.
Aggressive treatments given to younger patients with B-cell non-Hodgkin lymphoma may leave them vulnerable to other diseases later in life, according to a study in the AACR journal Cancer Epidemiology, Biomarkers & Prevention.
Patient expenses for cancer care exceed $21 billion in 2019, the FDA introduces stringent requirements for breast implants and more news of the week from Cancer Today.
THE FDA GRANTED ACCELERATED APPROVAL TO A TARGETED THERAPY FOR PATIENTS WITH CML RESISTANT TO OTHER THERAPEUTICS The U.S. Food and Drug Administration (FDA) approved the drug asciminib (Scemblix) for certain patients with Philadelphia...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More